Evidence map›Paper›PMID 37139460›Full record

ArticleMultiple sclerosis journal - experimental, translational and clinical

Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial.

Gary Cutter, Richard A Rudick, Carl de Moor, Carol M Singh, Elizabeth Fisher, Thijs Koster, Fred D Lublin, Jerry S Wolinsky, Henry McFarland, Steven Jacobson and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Gary CutterDepartment of Biostatistics, School of Public Health, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID https://orcid.org/0000-0002-8455-980X
Richard A RudickDepartment of Neurology, Biogen Inc, Cambridge, MA, USA, at the time of these analyses.
Carl de MoorBiostatistics, Biogen Inc, Cambridge, MA, USA, at the time of these analyses.
Carol M SinghBiogen Digital Health, Biogen Inc, Cambridge, MA, USA.
Elizabeth FisherValue Based Medicine, Biogen Inc, Cambridge, MA, USA, at the time of these analyses.
Thijs KosterGlobal Medical, Biogen Inc, Cambridge, MA, USA, at the time of these analyses.
Fred D LublinDepartment of Neurology, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, New York, NY, USA and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jerry S WolinskyMcGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.ORCID https://orcid.org/0000-0002-8197-2762
Henry McFarlandNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Steven JacobsonViral Immunology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Maria L NaylorGlobal Medical, Biogen Inc, Cambridge, MA, USA, at the time of these analyses.ORCID https://orcid.org/0000-0003-3844-6035
Biogen (United States) · USNational Institutes of Health · USAllen Institute for Brain Science · USThe University of Texas Health Science Center at Houston · USUniversity of Alabama at Birmingham · US

Funding

Extension of Combination Therapy for Multiple Sclerosis (eCombiRx)U01NS045719 · NINDS · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI LUBLIN, FRED D · 2003 to 2012
$44.7M
NINDS NIH HHS U01 NS045719
6 · The paper itself

Abstract

Background: CombiRx was a randomized, double-blind, placebo-controlled phase 3 trial in treatment-naive relapsing-remitting multiple sclerosis (RRMS) patients randomized to intramuscular interferon beta-1a (IM IFN beta-1a), glatiramer acetate (GA), or both therapies. Objective: This analysis investigated changes in serum neurofilament light-chain (sNfL) levels in response to treatment and assessed baseline sNfL as a predictor of relapse. Methods: RRMS patients treated with IM IFN beta-1a 30 µg weekly + placebo (n = 159), GA 20 mg/mL daily + placebo (n = 172), or IM IFN beta-1a + GA (n = 344) were included. A linear mixed model compared sNfL values over time. Cox regression models analyzed baseline sNfL and gadolinium-enhancing (Gd+) lesions as predictors of relapse. Results: In all treatment arms, the proportion of patients with sNfL ≥16 pg/mL decreased significantly from baseline to 6 months and was maintained at 36 months. A significantly higher percentage of patients with both baseline sNfL ≥16 pg/mL and ≥1 Gd+ lesion experienced relapses within 90 days compared to patients with sNfL <16 pg/mL and/or no Gd+ lesions. Conclusion: sNfL levels were reduced within 6 months and remained low at 36 months. Results suggest that the combination of lesion activity and sNfL was a stronger predictor of relapse than either factor alone.

Indexed as

beta-interferonbiomarkersdisease-modifying therapiesglatiramer acetateMultiple sclerosistreatment response

Identifiers

PMID37139460
PMCPMC10150429
OpenAlexW4367300072

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.